APO RESEARCH · REPORT
Varicella Vaccine
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Product & engineering
Understand the product.
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Selected research
Industry Research
Varicella Vaccine Industry Research Report 2026
Market perspective
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Global Varicella Vaccine key players include Merck, Shanghai Institute, Changsheng, Keygen, GSK, etc.
Asia is the largest market, with a share over 35%, followed by US and Europe, both have a share over 55%.
Read the full market overview
In terms of product, Freeze-Dried Powder is the largest segment, with a share over 50%. And in terms of application, the largest application is Kids Injection, followed by Adults Injection, etc.
Report Scope
This report quantifies the global Varicella Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (M Doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Varicella Vaccine Market by Company
Merck
GSK
Shanghai Institute
BCHT
Changsheng
Keygen
Green Cross
Biken
Varicella Vaccine Segment by Type
Injection
Freeze-Dried Powder
Varicella Vaccine Segment by Application
Kids Injection
Adults Injection
Varicella Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Varicella Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Varicella Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Varicella Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Varicella Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injection
- Freeze-Dried Powder
Applications
- Kids Injection
- Adults Injection
Companies covered
- Merck
- GSK
- Shanghai Institute
- BCHT
- Changsheng
- Keygen
- Green Cross
- Biken
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Varicella Vaccine Market Size (2021-2032)
- 2.2.2 Global Varicella Vaccine Sales (2021-2032)
- 2.2.3 Global Varicella Vaccine Market Average Price (2021-2032)
- 2.3 Varicella Vaccine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Injection
- 2.3.3 Freeze-Dried Powder
- 2.4 Varicella Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Kids Injection
- 2.4.3 Adults Injection
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Varicella Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Varicella Vaccine Sales (M Doses) of Manufacturers (2021-2026)
- 3.3 Global Varicella Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Varicella Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Varicella Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Varicella Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Varicella Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Varicella Vaccine, Established Date
- 3.9 Global Varicella Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck
- 4.1.1 Merck Company Information
- 4.1.2 Merck Business Overview
- 4.1.3 Merck Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck Varicella Vaccine Product Portfolio
- 4.1.5 Merck Recent Developments
- 4.2 GSK
- 4.2.1 GSK Company Information
- 4.2.2 GSK Business Overview
- 4.2.3 GSK Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GSK Varicella Vaccine Product Portfolio
- 4.2.5 GSK Recent Developments
- 4.3 Shanghai Institute
- 4.3.1 Shanghai Institute Company Information
- 4.3.2 Shanghai Institute Business Overview
- 4.3.3 Shanghai Institute Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Shanghai Institute Varicella Vaccine Product Portfolio
- 4.3.5 Shanghai Institute Recent Developments
- 4.4 BCHT
- 4.4.1 BCHT Company Information
- 4.4.2 BCHT Business Overview
- 4.4.3 BCHT Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 BCHT Varicella Vaccine Product Portfolio
- 4.4.5 BCHT Recent Developments
- 4.5 Changsheng
- 4.5.1 Changsheng Company Information
- 4.5.2 Changsheng Business Overview
- 4.5.3 Changsheng Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Changsheng Varicella Vaccine Product Portfolio
- 4.5.5 Changsheng Recent Developments
- 4.6 Keygen
- 4.6.1 Keygen Company Information
- 4.6.2 Keygen Business Overview
- 4.6.3 Keygen Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Keygen Varicella Vaccine Product Portfolio
- 4.6.5 Keygen Recent Developments
- 4.7 Green Cross
- 4.7.1 Green Cross Company Information
- 4.7.2 Green Cross Business Overview
- 4.7.3 Green Cross Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Green Cross Varicella Vaccine Product Portfolio
- 4.7.5 Green Cross Recent Developments
- 4.8 Biken
- 4.8.1 Biken Company Information
- 4.8.2 Biken Business Overview
- 4.8.3 Biken Varicella Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Biken Varicella Vaccine Product Portfolio
- 4.8.5 Biken Recent Developments
5 Global Varicella Vaccine Market Scenario by Region
- 5.1 Global Varicella Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Varicella Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Varicella Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Varicella Vaccine Sales by Region: 2027-2032
- 5.3 Global Varicella Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Varicella Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Varicella Vaccine Revenue by Region: 2027-2032
- 5.4 North America Varicella Vaccine Market Facts & Figures by Country
- 5.4.1 North America Varicella Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Varicella Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Varicella Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Varicella Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Varicella Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Varicella Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Varicella Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Varicella Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Varicella Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Varicella Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Varicella Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Varicella Vaccine Market Facts & Figures by Country
- 5.7.1 South America Varicella Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Varicella Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Varicella Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Varicella Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Varicella Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Varicella Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Varicella Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Varicella Vaccine Sales by Type (2021-2032)
- 6.1.1 Global Varicella Vaccine Sales by Type (2021-2032) & (M Doses)
- 6.1.2 Global Varicella Vaccine Sales Market Share by Type (2021-2032)
- 6.2 Global Varicella Vaccine Revenue by Type (2021-2032)
- 6.2.1 Global Varicella Vaccine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Varicella Vaccine Revenue Market Share by Type (2021-2032)
- 6.3 Global Varicella Vaccine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Varicella Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Varicella Vaccine Sales by Application (2021-2032) & (M Doses)
- 7.1.2 Global Varicella Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Varicella Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Varicella Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Varicella Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Varicella Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Varicella Vaccine Value Chain Analysis
- 8.1.1 Varicella Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Varicella Vaccine Production Mode & Process
- 8.2 Varicella Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Varicella Vaccine Distributors
- 8.2.3 Varicella Vaccine Customers
9 Global Varicella Vaccine Analyzing Market Dynamics
- 9.1 Varicella Vaccine Industry Trends
- 9.2 Varicella Vaccine Industry Drivers
- 9.3 Varicella Vaccine Industry Opportunities and Challenges
- 9.4 Varicella Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst